Literature DB >> 17220732

Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).

Anand Khurana1, Val M Runge, Mohanram Narayanan, John F Greene, Allan E Nickel.   

Abstract

OBJECTIVES: Nephrogenic systemic fibrosis (NSF) is a rare acquired disorder that was first recognized in 1997. Presented is a retrospective review of 6 cases of NSF diagnosed by skin biopsy in our institution during the past 4 years and their relationship to gadodiamide exposure. METHODS AND
RESULTS: Patient age ranged from 23 to 71 years. The onset of symptoms consistent with NSF was between 19 days and 2 months after gadodiamide exposure. Five patients had severe renal impairment and started dialysis around the period of gadodiamide exposure (1 day before the 37 days after contrast administration). The sixth patient had a clotted access at the time of a contrast-enhanced magnetic resonance venogram and was hence not being adequately dialyzed. The dose of gadodiamide ranged from 16 to 40 mL (0.11 to 0.36 mmol/kg). Despite having normal serum bicarbonate, 5 of the 6 patients had an elevated anion gap metabolic acidosis.
CONCLUSIONS: In our 6 patients, all had either failing native or transplant kidneys at the time of gadodiamide exposure. The development of NSF was temporally related to gadodiamide injection, suggesting as the etiology dechelation of the agent and thus emphasizing the need for change in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220732     DOI: 10.1097/01.rli.0000253505.88945.d5

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  39 in total

1.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

Review 2.  Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis?

Authors:  Alexander R Rosenkranz; Thomas Grobner; Gert J Mayer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

3.  [Nephrogenic systemic fibrosis. Medical detective work in the 21st century].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

4.  Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent.

Authors:  Narasimharao Bhagavathula; Marissa DaSilva; Muhammad N Aslam; Michael K Dame; Roscoe L Warner; Yiru Xu; Gary J Fisher; Kent J Johnson; Richard Swartz; James Varani
Journal:  Invest Radiol       Date:  2009-08       Impact factor: 6.016

Review 5.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

6.  [Nephrogenic systemic fibrosis].

Authors:  W Samtleben
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

Review 7.  Nanoparticles for imaging and treating brain cancer.

Authors:  Joseph D Meyers; Tennyson Doane; Clemens Burda; James P Basilion
Journal:  Nanomedicine (Lond)       Date:  2013-01       Impact factor: 5.307

8.  Application of magnetic resonance urography in diagnosis of congenital urogenital anomalies in children.

Authors:  Seyedmehdi Payabvash; Abdol-Mohammad Kajbafzadeh; Parisa Saeedi; Zhina Sadeghi; Azadeh Elmi; Mehrzad Mehdizadeh
Journal:  Pediatr Surg Int       Date:  2008-07-31       Impact factor: 1.827

9.  Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.

Authors:  Javier Perez-Rodriguez; Shenghan Lai; Benjamin D Ehst; Derek M Fine; David A Bluemke
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

10.  Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.

Authors:  Robert F Reilly
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.